Alvotech vs BioNTech
ALVO and BNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALVO and BNTX compare
Alvotech grew revenue faster over the last twelve months (19.7% versus 4.3% for BioNTech).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALVO | BNTX |
|---|---|---|
| Size and price | ||
| Share price | $4.65 | $88.17 |
| Change, 1 year | −41.1% | −14.7% |
| Change, 5 years | −53.0% | −59.3% |
| Beta (5Y) | 0.47 | 0.82 |
| Employees | 1,000 | 500 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 19.7% (better) | 4.3% |
| Revenue growth, 5Y average | 54.5% (better) | 42.9% |
| Profitability | ||
| Gross margin | 59.8% | 77.6% (better) |
| Operating margin | 13.3% (better) | −49.0% |
| Net margin | – | −39.6% |
| FCF margin | −19.6% | 9.8% (better) |
| Financial health | ||
| Net debt / EBITDA | 10.02 | – |
| Interest coverage | 0.5× (better) | −20.1× |
| Current ratio | 1.65 | 7.54 (better) |
| Piotroski F-score | – | 5 |
| Ownership | ||
| Held by institutions | – | 18.9% |
| Held by insiders | 67.7% | 58.1% |
| Insider net buying, 12 months | – | −$69.2M |
Go deeper
- ALVO stock overview
- ALVO income statement
- ALVO valuation and score
- BNTX stock overview
- BNTX income statement
- BNTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.